NCT02181192

Point in Time of Radiotherapy for Patients With Biochemical Recurrent Prostate Carcinoma

Postoperative Prostate Carcinoma Recurrence: Instant Radiotherapy Versus Radiotherapy With Additional Imaging With PSA Value >= 1

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: University of Erlangen-Nürnberg Medical School · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

PSA-recurrence prostate carcinoma is associated with two general problems. 1. Localisation of PSA-recurrence is unconfident. In many cases it's not clear if a local, locoregional oder systemic relapse is available. 2. There is no standard therapy proved by randomised clinical trials. Recommended radiotherapy starting with PSA-value \< 0.5 ng/ml according to german S3 guidelines is based on retrospective data. These difficulties may lead to a therapy potentially not adapted to patients situation of disease.This study aims to randomised examine if an instant radiotherapy of prostate PSA-recurrence (PSA-value between 0.2 - 0.99 ng/ml) or a delayed radiotherapy with additional imaging (PSA value \>= 1 ng/ml) including PET/CT and bone scintigraphy for reliable information about tumor location and expansion is beneficial regarding therapy efficiency, quality of life and social economic aspects.

Conditions

• Prostate Cancer
• Recurrence

Interventions

Type	Name	Description
DEVICE	PET/CT	PET/CT
RADIATION	Instant Radiotherapy according to guidelines	Instant Radiotherapy according to guidelines
RADIATION	Radiotherapy after achievement of PSA marginal value	Radiotherapy after achievement of PSA marginal value

Timeline

• Start date: 2017-07-01
• Primary completion: 2019-07-01
• Completion: 2020-07-01
• First posted: 2014-07-03
• Last updated: 2016-08-01